By otakuyassine3@gmail.com 
Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $32.32 and traded as high as $36.71. Simulations Plus shares last traded at $36.05, with a volume of 151,390 shares.
Analysts Set New Price Targets
Several research analysts have recently commented on the stock. KeyCorp lifted their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, January 24th. BTIG Research reduced their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Stephens assumed coverage on shares of Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price objective on the stock. Finally, William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Simulations Plus has an average rating of “Moderate Buy” and a consensus target price of $49.40.
Check Out Our Latest Analysis on Simulations Plus
Simulations Plus Stock Performance
The company’s 50 day simple moving average is $30.91 and its 200 day simple moving average is $32.32. The stock has a market cap of $724.24 million, a price-to-earnings ratio of 90.13 and a beta of 0.83.
Insiders Place Their Bets
In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares of the company’s stock, valued at $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 19.40% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Conestoga Capital Advisors LLC boosted its stake in Simulations Plus by 15.0% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock worth $62,090,000 after purchasing an additional 290,414 shares during the period. State Street Corp lifted its holdings in shares of Simulations Plus by 4.7% in the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after purchasing an additional 28,953 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Simulations Plus by 4.4% in the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after buying an additional 18,924 shares during the period. Tributary Capital Management LLC grew its holdings in shares of Simulations Plus by 21.7% during the fourth quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company’s stock valued at $11,047,000 after buying an additional 70,526 shares in the last quarter. Finally, Royce & Associates LP raised its position in Simulations Plus by 56.6% during the fourth quarter. Royce & Associates LP now owns 371,797 shares of the technology company’s stock valued at $10,369,000 after buying an additional 134,381 shares during the period. Institutional investors own 78.08% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Recommended Stories
Receive News & Ratings for Simulations Plus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Simulations Plus and related companies with MarketBeat.com’s FREE daily email newsletter.